Biofrontera, Inc. (BFRI)
0.8698
+0.01
(+0.79%)
USD |
NASDAQ |
Jun 11, 10:52
Biofrontera SG&A Expense (Quarterly) : 11.00M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 11.00M |
| December 31, 2025 | 8.746M |
| September 30, 2025 | 10.37M |
| June 30, 2025 | 10.60M |
| March 31, 2025 | 8.66M |
| December 31, 2024 | 8.216M |
| September 30, 2024 | 8.426M |
| June 30, 2024 | 7.947M |
| March 31, 2024 | 9.246M |
| December 31, 2023 | 9.06M |
| September 30, 2023 | 8.693M |
| June 30, 2023 | 11.55M |
| Date | Value |
|---|---|
| March 31, 2023 | 9.827M |
| December 31, 2022 | 10.21M |
| September 30, 2022 | 7.936M |
| June 30, 2022 | 10.02M |
| March 31, 2022 | 7.711M |
| December 31, 2021 | 9.277M |
| September 30, 2021 | 17.25M |
| June 30, 2021 | 5.748M |
| March 31, 2021 | 4.922M |
| September 30, 2020 | 4.302M |
| June 30, 2020 | 3.669M |
| March 31, 2020 | 5.983M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Rapport Therapeutics, Inc. | 11.50M |
| ANI Pharmaceuticals, Inc. | 73.66M |
| Corcept Therapeutics, Inc. | 145.36M |
| Assertio Holdings, Inc. | 11.14M |
| Veru, Inc. | 4.073M |